Slide 1: Immunic Therapeutics
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 216 of the Securities
Slide 3: Clinical-Stage Biopharmaceutical Company
CLINICAL-STAGE Innovative pipeline: BIO PHARMACEUTI CAL First-in-class oral drugs with unique modes of actions for multiple sclerosis COM PANY (NAS DAQ: IM UX) and gastrointestinal diseases Dedicated to improving the lives of patients with chronic inflammatory and autoimmune diseases aan uy Positive
Slide 4: Leadership Team
Leadership Team Company is Led by an Experienced Management Team Daniel Vitt, Jason Tardio, Andreas Muehler, PhD MBA MD, MBA Chief Executive President & Chief Chief Medical Officer Operating Officer Officer Hella Kohlhof, PhD Chief Scientific Officer Patrick Walsh Chief Business Officer Glenn Whaley
Slide 5: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3. Key Program Updates Vidofludimus Calcium (imu-838)" Progressive Multiple Sclerosis (PMS) — CALLIPER Trial Ulcerative Colitis (UC) - CALDOSE-1 Trial Phase 2 E
Slide 6: Targeted to Elevate the Standard of Care for the Full Spectrum of MS Patients
Slide 7: Vidofludimus Calcium Has the Potential to Transform the Oral MS DMT Market
Vidofludimus Calcium Has the Potential to Transform the Oral Multiple Sclerosis DMT Market Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention First-in-class, dual mode of action approach designed to address the full spectrum of disease: = Nurr1 activation provides dir
Slide 8: Regardless of the Subtype, the Outcome of Every Patient Journey in MS Is Disability
Regardless of the Subtype, the Outcome of Every Patient Journey in Multiple Sclerosis Is Physical and/or Cognitive Disability -Ge fe] (ye? ° 10 a5 2.0 25 3.0 3.5 4.0 45 5.0 5.5 6.0 6.5 7.0 9.0 95 10 1.0 9.0 No deity, minimal Confined to be, can sgnsofMs Silcommuniate and cn 6 Death by MS While over
Slide 9: Potential to be the First and Only Oral DMT Approved for Both Relapsing and Progressive MS
Vidofludimus Calcium Has the Potential to be the First and Only Oral DMT Approved for Both Relapsing and Progressive MS Relapsing MS (RMS) Progressive MS (PMS) Relapsing MS Non-Active SPMS. Primary Progressive MS = Relapses and MRI lesions dominate Relapses have stopped, but disability Disability wo
Slide 10: A Large and Growing Global Market Where Multiple Blockbusters Coexist
A Large and Growing Global Market Where Multiple Blockbusters Coexist Many brands are generating in excess of $1 billion in global annual sales in 202411 Ocrevus® $7.6 billion Kesimpta® $3.2 billion Tysabri® $1.7 billion Tecfidera® & Vumerity® $1.6 billion Mavenclad® $1.15 billion Avonex® & Plegridy
Slide 11: Oral DMTs Will Continue to Play a Big Role as Important Treatment Options
Oral DMTs Will Continue to Play a Big Role as Important Treatment Options Global Market Share by Drug Class 2022 vs. 2032) IQ . While anti-CD20 class of therapies continues to grow, oral class still expected to capture over 1/3 of the global market = 42% of patients prefer oral medicines?! = Early-l
Slide 12: Multiple MS Patient Segments Could Benefit from Vidofludimus Calcium
Multiple MS Patient Segments Could Benefit from Vidofludimus Calcium Older patients where . = : O Newly diagnosed patients immunosuppression is a concern Patients switching therapies due to disabili d pati x = pies due to disability Untreated patients a worsening Patients switching < - 5 Patients wi
Slide 13: Derisked Near-Term Opportunity With $3-7 Billion Peak Potential
Vidofludimus Calcium: Derisked Near-Term Opportunity With $3-7 Billion Peak Potential Indication Status Clinical Evidence Eligible Population Next Milestones Potential Peak Sales RMS Phase 3 78% reduction of new Gd+ lesions (Phase 2) ~900K Phase 3 completion expected end of 2026 $1-2B naSPMS Phase 3
Slide 14: Global Market for PPMS Treatment Estimated to Be $6+ Billion
& Global Market for PPMS Treatment Estimated to Be $6+ Billion J But Less Than Half of All Diagnosed Patients Are Treated Today diagnosed PPMS patients of diagnosed PPMS patients in PPMS sales for the only in the US & EUS are currently on a DMT approved product Total global market for PPMS estimated
Slide 15: First-in-Class, Potent Nurr1 Activator and Selective DHODH Inhibitor
Slide 16: Vidofludimus Calcium Addresses Smoldering Neurodegeneration
Vidofludimus Calcium Addresses Smoldering Neurodegeneration SS First-in-Class Nurr1 Activator, Targeting Improvement of Physical and Mental Ability of Multiple Sclerosis Patients Nurri Activator = Direct and indirect neuroprotective effects = Involved in protecting relevant neurons from cell death =
Slide 17: Vidofludimus Calcium Activates Nurr1, Shown to Increase Neuronal Survival
Vidofludimus Calcium Activates Nurr1, Shown to Increase Neuronal Survival a Nurr1 Binding rene Gene Expression Regulation sone Improves Neuronal Survival Nurr1 isa transcription factor binding to DNAM) Vidofludimus calcium binds to and strongly activates Nurr1 activity with nM values Vidofludimus ca
Slide 18: Clinical Trials Overview in Multiple Sclerosis
Vidofludimus Calcium: Clinical Trials Overview in Multiple Sclerosis (MS) ENSURE-2 | RELAPSING MS . Phase 3 Fully enrolled, n=1100 patients Top-Line Data Expected End of 2026 for both ENSURE trials ENSURE-1 | RELAPSING MS Phase 3 Fully enrolled, n=1121 patients PROGRESSIVE MS Redu C CALLIPER 2 CDW i
Slide 19: Development in Relapsing Multiple Sclerosis (RMS)
Slide 20: Could be the First Treatment Option for Relapsing MS Fulfilling Unmet Needs
Vidofludimus Calcium Could be the First Treatment Option for Relapsing MS Fulfilling the Current Unmet Needs of Patients Gi Goals for New Relapsing Multiple Sclerosis Treatments = Developing a new therapy offering: — Neuroprotection and effect on progression independent of relapse activity (PIRA) —
Slide 21: EMPhASIS: Completed Phase 2 Trial in Relapsing-Remitting MS
EMPhASIS: Completed Phase 2 Trial in Relapsing-Remitting MS NCT03846219 Viet Trial Met Key LG Efficacy and Safety Endpoints = Randomized 268 patients in 36 centers across four fe Coordinating Investigator European countries = Vidofludimus calcium showed strong activity in relapsing- remitting MS pop
Slide 22: EMPhASIS: Strong Reduction of MRI Lesion Activity
EMPhASIS: Strong Reduction of MRI Lesion Activity Primary Endpoint Hit With High Statistical Significance, Pooled Cohorts 1 & 2 Reduction in Cumulative CUA Lesions up to Week 24 Reduction in Gd+ Lesions up to Week 24 o 0 7 0 5 13% 8 é -10 4s -10 -20 4 -20 5 30 35 30 4 -40 3 -40 -50 25 -50 3 “71% -60
Slide 23: EMPhASIS: Reduction of Serum NfL Concentrations Observed
EMPhASIS: Reduction of Serum NfL Concentrations Observed Versus Placebo After 24 Weeks, Pooled Cohorts 1 & 2 50% -50% 10 mg IMU-838 Displayed are median valuesof cfferances betvaen percentage change of serum neurofilament light chain concentration (Hodges'.zhmann estimation) trastment vs placebo Dat
Slide 24: EMPhASIS: Reduced Confirmed Disability Worsening Events
EMPhASIS: Reduced Confirmed Disability Worsening Events End of 24-Week Blinded Treatment Period CDW Events at the End of the 24-Week Blinded Treatment Period 4.0% 3.7% 3.7% 3.5% 3.0% = Signal in preventing 12-week and 2.5% 24-week confirmed disability 2.0% 16% 16% worsening events as compared to ue
Slide 25: EMPhASIS: Low Rates of Confirmed Disability Worsening Events
EMPhASIS: Low Rates of Confirmed Disability Worsening Events Open-Label Extension Period, 196 Patients Reaching 144 Weeks of Treatment Proportion of patients free of 12-week confirmed disability worsening after up to 144 weeks of open-label extension vidofludimus calcium treatment 100.0% 98.0% 97.2%
Slide 26: Unrivaled Safety and Tolerability Profile
Vidofludimus Calcium: Unrivaled Safety and Tolerability Profile Observed in Multiple Clinical Trials = Safety profile similar to placebo: no general safety signals observed in clinical trials so far = No increased rates of diarrhea, neutropenia, or alopecia = No increased rates of infections and inf
Slide 27: EMPhASIS: Well-Tolerated With Adverse Events Similar to Placebo
EMPhASIS: Vidofludimus Calcium Well-Tolerated With Adverse Events Similar to Placebo Vidofludimus Vidofludimus Safety & Tolerability Endpoints Placebo Calcium 30mg Calcium 45mg ‘Any treatment-emergent adverse event 44% 45% 41% Treatment-emergent adverse events occurring in >5% of total patients by p
Slide 28: EMPhASIS: Patients Feel Well-Treated With Vidofludimus Calcium
EMPhASIS: Patients Feel Well-Treated With Vidofludimus Calcium Reflected in Low Discontinuation Rates for Vidofludimus Calcium-Treated RRMS Patients, Considerably Lower Than Placebo* Vidofludimus Glatiramer ae eats Aubagio® 1 Tecfidera® #1 Gilenya® (4) Zeposia® (51 Administration Oral Injectable Ora
Slide 29: ENSURE: Ongoing Pivotal Phase 3 Trials in Relapsing MS
ENSURE: Ongoing Pivotal Phase 3 Trials in Relapsing MS NCT05134441 & NCT05201638 x Coordinating Investigator Two Multicenter, Randomized, Double-Blind Phase 3 Trials Robert J. Fox, M.D. Cleveland Clinic Included Patient Population: Px Relapsing Forms of MS Adult patients aged 18 to 55 years Establis
Slide 30: Development in Progressive Multiple Sclerosis (PMS)
Slide 31: Huge Unmet Medical Need Exists in PPMS
Huge Unmet Medical Need Exists in PPMS, An Underdiagnosed and Tougher to Treat Patient Population O 31 | © immunic, inc. | Aug/07/2025 = PPMS, which affects 10-15% of people diagnosed with MS, is characterized by a steady worsening of neurological function from the beginning of the disease, without
Slide 32: CALLIPER: Phase 2 Clinical Trial in Progressive MS
CALLIPER: Phase 2 Clinical Trial in Progressive Multiple Sclerosis NCT05054140 (Open-Label) Screening Period Main Treatment Period (Blinde Scenetm 45 mg IMU-838 (N=235) ! Placebo (N=232) 45mg IMU-838 Main Analysis ! D-28to-3 DBto-L bt wea was w72 Visits every 12 weeks MRI every 24 weeks EoMT* up tp
Slide 33: CALLIPER: Patient Demographics and Baseline Characteristics
CALLIPER: Patient Demographics and Baseline Characteristics Total Study Population of 467 Enrolled Patients Progressive Disease Subtypes Baseline Characteristics Baseline Patient Characteristics Total (N=467) Age [years], median (min-max) 51.0 (21-65) Gender (n and % female) 302 (64.7%) = Primary Ra
Slide 34: CALLIPER successfully demonstrated neuroprotective potential
CALLIPER successfully demonstrated the neuroprotective potential of vidofludimus calcium in PMS patients Clinically meaningful risk reduction of confirmed disability worsening of 24% in overall PMS population and even more prominent 31% reduction in PPMS population
Slide 35: CALLIPER: Reduced Time to 24wCDW in Overall Population and All Subtypes
CALLIPER: Vidofludimus Calcium Reduced Time to 24wCDW in Overall Study Population and All Subtypes Compared to Placebo Overall CALLIPER PPMS naSPMS aSPMS Patient Population (N=467) (N=152) (N=268) (N=47) HR (Kaplan Meier) 0.762 0.687 0.808 0.663 95 % Cl [0.479; 1.210] [0.330; 1.430] [0.418, 1.564] [
Slide 36: CALLIPER: Significantly Reduced EDSS Increase from Baseline
CALLIPER: Vidofludimus Calcium Significantly Reduced EDSS Increase from Baseline Compared with Placebo MMRM Analysis (All Patients): Change from Baseline in EDSS score 0.38 —e- Vidofludimus Calcium Placebo 03 * Statistically significant (p<0.05) ** Statistically significant (p<0.01) 0.25 02 0.18 Ls
Slide 37: Comparison CALLIPER Versus ORATORIO Trials in PPMS Population
Comparison CALLIPER Versus ORATORIO Trials in PPMS Population ORATORIO* CALLIPER (N=732) (N=152) Mean Age (Years) 44.6 474 Female (N,%) 361 (49.3%) 93 (61.1%) EDSS - Mean 4.7 4.9 EDSS - Median 45 45 Gd+ Lesions at Baseline MRI (N,%) 26.6% 17.8% a = = 37 | © immunic, inc. | Aug/07/2025, & Immunic
Slide 38: CALLIPER: Substantially Reduced 24wCDW in Patients Without Gd+ Lesions
CALLIPER: Vidofludimus Calcium Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline Time to 24wCDW With No Evidence of Gd+ Lesions at Baseline Group Numbenot HR 95 % Cl p-value RRR tt24wCDW Patients All Patients 391 0.663 0.394, 1.115] 0.120 33.7% PPMS 125 0.656 (0.294; 1.464] 0.
Slide 39: CALLIPER: Top-Line Data Confirmed Favorable Safety and Tolerability
CALLIPER: Top-Line Data Confirmed Favorable Safety and Tolerability Profile of Vidofludimus Calcium Observed in Previous Clinical Trials Number of Patients With Any TEAE and SAE Vidofludimus Placebo Calcium 5 A a . oe Neos No new safety signals identified Any TEAE, n(%) 163 (69.4) 159 (68.5) = Occur
Slide 40: Positive Data from Phase 2 CALLIPER Trial
40 | © immunic, inc. | Aug/07/2025 | Ln | Positive Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Clinically meaningful risk reduction of 24wCDW by 24% in overall study population; even more prominent 31% reduction in high unmet need population of PPMS Rem
Slide 41: DHODH Inhibition Provides Broad-Spectrum Antiviral Activity
Vidofludimus Calcium: DHODH Inhibition Provides Broad- Spectrum Antiviral Activity Against Different Pathogenic Viruses Inhibits Epstein-Barr Virus (EBV) Showed Dose-Dependent IN Decreased Number of Opportu- Replication and Reactivation Inhibition of EBV Reactivation nistic SARS-CoV-2 Infections By
Slide 42: Several Layers of Patents Protecting Vidofludimus Calcium
Several Layers of Patents Protecting Vidofludimus Calcium Eight Independent Patent Families Protecting Vidofludimus Calcium Calcium salt New polymorph and = IP for superior calcium salt and specific polymorph of the drug product specific salt/hydrate _ . . , and foarulation — Additional patent direc
Slide 43: Vidofludimus Calcium in Multiple Sclerosis
Vidofludimus Calcium in Multiple Sclerosis Consistent and Differentiated Results to Date Support Straightforward Path Towards Potential Regulatory Approvals EMPhASIS: CALLIPER: CALLIPER: Potential Positive phase 2 RRMS data demonstrating Positive phase 2 PMS Positive phase 2 PMS data RMS NDA statist
Slide 44: Restoring a Healthy Gut through Renewal of the Bowel Wall
Slide 45: IMU-856 Targets Physiological Intestinal Epithelial Regeneration
IMU-856 Targets Physiological Intestinal Epithelial Regeneration and Restoration of Gut Cell Function = Innovative oral therapeutic approach potentially applicable to a broad range of gastrointestinal disorders = Targets physiological intestinal epithelial regeneration, including gut hormon-producin
Slide 46: Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall
Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall and Barrier Function by a New Innovative Targeted Mechanism Di d Gut Wall Healthy Gut Wall amaged Gut Wal jealthy Gut Wal IMU-856: = First-in-class modulator of Bowel lumen Bowel lumen irtuin 6 (SIRTS), t 6 antigens, microbiome, nutrients anti
Slide 47: SIRT6 Target Is Highly Expressed in Gut Epithelial Cells
SIRT6 Target Is Highly Expressed in Gut Epithelial Cells G Highest mRNA Expressions in Paneth Cells, Enterocytes, © Goblet Cells and Enteroendocrine Cells such as L-Cells ye jm li é ‘ esc Macrophage Left: tp: //wrw.prowinatlas.or// Right: Peterson, L, Arts D. Nat Rev Immunol 14, 141-153 (2014) SIRT:
Slide 48: IMU-856 Enhances the Natural Regenerative Process in the Gut
IMU-856 Enhances the Natural Regenerative Process in the Gut Gut wall renewal is a normal physiological process ‘ els Phyiereeice: Asymmetric cell division renews stem cells 1. Regeneration begins in the crypts, where and regenerates the gut wall intestinal stem cells are located 2. Stem cells under
Slide 49: Dose-Dependent Increase of GLP-1 in Patients
Slide 50: Intestinal Production of GLP-1 Mediates Effects on Body Weight
Intestinal Production of GLP-1 Mediates Effects on Body Weight Ov . . Main Physiologic Effects of GLP-1 GLP-1: Glucagon-Like Peptide-1 GLP-1 = Peptide hormone generated through enzymatic breakdown of proglucagon = Endocrine hormone, secreted by enteroendocrine L-cells located in the distal jejunum,
Slide 51: IMU-856: Effects on Body Weight and Blood GLP-1 Levels
IMU-856: Effects on Body Weight in Preclinical Experiment and on Blood GLP-1 Levels in Celiac Disease Clinical Trial SS 6-Months /n Vivo Study Phase 1b Clinical Trial of IMU-856 = Regulated GLP study"! to support clinical development = Designed to explore effects of gluten challenge in a celiac * Da
Slide 52: In a 6-Months In Vivo Study, IMU-856 Dose-Dependently Reduced Weight Gain
In a 6-Months /n Vivo Study, IMU-856 Dose-Dependently Reduced Weight Gain Body Weight - % Change From Baseline Dose-dependent effect on body weight gain Linked to reduced food consumption Effect in both males and females No effect on general health condition 2 40 60 80 10 1% 1 16 19 20 Study day 10
Slide 53: IMU-856 Dose-Dependently Increased GLP-1 in Celiac Disease Patients
Confirmation of Effects as Part of Phase 1b Clinical Trial: IMU-856 Dose-Dependently Increased GLP-1 in Celiac Disease Patients 28-day phase 1b clinical trial of IMU-856 in celiac disease GLP-1 Plasma Concentration = Patients measured for plasma GLP-1 concentrations: Median % Change from Baseline to
Slide 54: Main Secretory Epithelial Cells Express SIRT6 Target
Main Secretory Epithelial Cells of the Small Intestine and Colon Epithelium All Have Been Shown to Express SIRT6 Target =a Produce and release a protective mucus layer, with the main so component of this mucus being a protein called mucin Goblet 3 cell = ot Secret gastrointestinal hormones: such as
Slide 55: A Novel Mechanism Beyond Existing GLP-1, GLP-2, GIP Mimetics
IMU-856: A Novel Mechanism Offering Potential to Go Beyond Existing GLP-1, GLP-2, GIP Mimetics G SIRT6 Targeting Approach S Incretin Mimetics IMU-856 GLP-1, GLP-2, GIP = Functional improvement of = Providing synthetic peptides that mimic the enteroendocrine and other epithelial cells natural hormone
Slide 56: Obesity Market Expected to Reach More Than $170 Billion Globally by 2031
Obesity Market Expected to Reach More Than $170 Billion Globally by 2031! 7A Unmet Needs Still Exist to Address This Growing call Medical Challenge = Obesity and overweight are among the fastest growing and most prevalent chronic human conditions in the world affecting ~2.5 billion adults worldwide!
Slide 57: Demonstrated Clinical Proof-of-Concept in a Phase 1b Clinical Trial
Slide 58: Celiac Disease Currently Has No Adequate Treatment Options
Celiac Disease Currently Has No Adequate Treatment Options = Two million patients diagnosed with celiac disease in the ; _ or, . (1,21 10 mg of gluten is the total limit for all US; more than one million more undiagnosed!* foods combined for the entire day. = Most studies report between 24% and 47%!
Slide 59: IMU-856 Demonstrated Clinical Proof-of-Concept in Celiac Disease
IMU-856 Demonstrated Clinical Proof-of-Concept in a Phase 1b Clinical Trial in Celiac Disease Proof-of-Concept Study Designed as a Gluten Challenge Trial Flow Chart of Phase 1b Clinical Trial in Celiac Disease Day 1-28: Treatment IMU-8! = Celiac disease used as disease model to provide clinical proo
Slide 60: IMU-856 Protected Against Gluten-Induced Decrease in Villous Height
IMU-856 Protected Against Gluten-Induced Decrease in Villous Height as Compared to Placebo Absolute change in villous height (um) between Baseline and Day 29 Day 1-28: Treatment IMU-856/placebo o Day 14-28: Gluten challenge with 6 g/daily -10 Mean -22.5 -20 SD 51.1 Baseline: EGD with biopsy um} -30
Slide 61: IMU-856 Improved Uptake of Vitamin B12 and Zinc
IMU-856 Improved Uptake of Actively Transported Essential Nutrients Vitamin B12 and Zinc dl Vitamin B12 Zinc Mean change from Baseline to Day 29 in vitamin B12 (pmol/L) Mean change from Baseline to Day 29 in zinc (mol/L) 80 a os 2 Loa 06 c a 04 5 40 Mean 45.8 3 S sp94.4 B 02 © 20 Zo rs 5 2 g 02 - °
Slide 62: Summary
Slide 63: Summary: Vidofludimus Calcium Is a Derisked Near-Term Opportunity
Summary: Vidofludimus Calcium Is a Derisked Near-Term Opportunity a Innovative clinical Pipeline: First-in-class oral drugs with unique modes of actions for multiple sclerosis and gastrointestinal diseases in various phases of clinical development < Relapsing MS opportunity is meaningful and de-risk
Slide 64: Thank You!
Thank You! Jessica Breu Vice President Investor Relations & Communications G Phone: +1-332-255-9819 ©& Email: ir@imux.com © Web: www.imux.com 64 | © immunic, inc. | Aug/07/2025 Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grafelfing (Muni
Slide 65: Time to 24-Week Confirmed Disability Worsening (Based on EDSS)
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) All Patients — All Disease Subtypes Combined — Kaplan-Meier Analysis of 24wCDW Time to 24wCDW kK Relative Risk Reduction 0.5: 04 0.3 0.2 Propotion Free of 24wCDW Strata —— IMU-838 Placebo 48 72 Time Since Randomization (weeks) Overall CA
Slide 66: Time to 24-Week Confirmed Disability Worsening: PPMS Subpopulation
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) PPMS Subpopulation — Kaplan-Meier Analysis of 24wCDW Strata == IMU-838 Placebo roy Time to 24wCDW 05 Relative Risk Reduction 04 PPMS Patient z Population 8 2 = 03 HR (Kaplan-Meier) 0.687 5 02 RRR 31.3% 8 95% Cl [0.330, 1.430] 01 p-value
Slide 67: Time to 24-Week Confirmed Disability Worsening: naSPMS Subpopulation
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) naSPMS Subpopulation — Kaplan-Meier Analysis of 24wCDW Strata —— IMU-838 Placebo Ql Time to 24wCDW 05 Relative Risk Reduction 04 naSPMS Patient z Population 8 2 BR 03 HR (Kaplan-Meier) 0.808 © 02 RRR 19.2% 95% Cl [0.418, 1.564] 0.1 —— =
Slide 68: Time to 24-Week Confirmed Disability Worsening: aSPMS Subpopulation
Time to 24-Week Confirmed Disability Worsening (Based on EDSS) aSPMS Subpopulation — Kaplan-Meier Analysis of 24wCDW Time to 24wCDW kK Relative Risk Reduction Strata 0.5 04 0.3 0.2 Propotion Free of 24wCDW 01 — IMU-838 Placebo aSPMS Patient Population HR (Kaplan-Meier) 0.663 RRR 33.7% 95% Cl [0.315,
Slide 69: Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline
Vidofludimus Calcium Substantially Reduced 24wCDW in Patients Without Gd+ Lesions at Baseline 0.5. id Patient Population 2 7 Without Gd+ Lesions 8 at Baseline = & 03 ES HR (Kaplan-Meier) 0.663 § 02 RRR 33.7% e 95% Cl [0.394, 1.115] 01 P-value 0.120 0 =o N 391 0 24 48 72 96 120 Strata == IMU-838 Plac
Slide 70: Substantially Reduced 24wCDW in PPMS Patients Without Gd+ Lesions
Vidofludimus Calcium Substantially Reduced 24wCDW in PPMS Patients Without Gd+ Lesions at Baseline Strata —— IMU-838 Placebo él Time to 24wCDW. 05 N Relative Risk Reduction PPMS Patient 04 Population Without a Gd+ Lesions at Ed Baseline 8 03 ¢ HR (Kaplan-Meier) 0.656 & 02 RRR 34.4% : 95% Cl (0.294;
Slide 71: CALLIPER: Brain Atrophy Endpoints Consistently Demonstrated Beneficial Effect
CALLIPER: Brain Atrophy Endpoints Consistently Demonstrated Beneficial Effect of Vidofludimus Calcium Compared to Placebo = Modest benefit on exploratory primary MRI endpoint: — : decreased annualized rate of whole brain atrophy: a, ~ — 4.13% improvement of vidofludimus calcium compared : to placebo
Slide 72: CALLIPER: Substantially Lowered Volume of New/Enlarging T2 Lesions
CALLIPER: Vidofludimus Calcium Substantially Lowered Volume of New/Enlarging T2 Lesions Compared to Placebo New or Enlarging T2 Lesions - Mean Volume Change (cm3) . Vidofludimus calcium From Baseline to Week 96 significantly reduced * | _Ly-vidottudimuscalcium — —e-Blacebo volume of new or enlarging